Stocktoria
EXELIXIS, INC. EXEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-04-11
EXELIXIS, INC. financials (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B |
| R&D expense | $825.0M | $910.4M | $1.0B | $891.8M | $693.7M |
| SG&A expense | $518.7M | $492.1M | $542.7M | $459.9M | $401.7M |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Income tax | $158.6M | $160.4M | $49.8M | $52.1M | $63.1M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| EPS (diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
| Operating cash flow | $884.3M | $700.0M | $333.3M | $362.6M | $400.8M |
| Free cash flow | $875.8M | $671.5M | $292.9M | $334.9M | $346.6M |
| Cash & equivalents | $482.5M | $217.4M | $263.0M | $501.2M | $647.2M |
| Inventory | $21.7M | $22.4M | $17.3M | $33.3M | $27.5M |
| Total assets | $2.8B | $2.9B | $2.9B | $3.1B | $2.6B |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M | $405.6M |
| Shareholders' equity | $2.2B | $2.2B | $2.3B | $2.5B | $2.2B |
Source: SEC EDGAR filings · CIK 0000939767 · as of 2026-01-02. Facts from filings plus Stocktoria's own computed scores — not investment advice.